Payment overview · 2025
General Payments
$1,485.99
84 reported records · 19 companies
Healthcare provider profile · identity verified
Joseph C La Mancusa, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · FINDLAY, OH · NPI 1487654497
Verified facts
What the public records show
CMS Open Payments records show Joseph C La Mancusa, MD received $1,485.99 in general payments during 2025 across 84 reported records.
MDD US Operations, LLC accounted for 41.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nuplazid, Nurtec Odt, Qulipta, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ubrelvy by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Nuplazid by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $617.07 | 41.5% | 37 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $154.82 | 10.4% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $81.92 | 5.5% | 4 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $79.25 | 5.3% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $68.31 | 4.6% | 3 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $67.36 | 4.5% | 4 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$52.78 | 3.5% | 3 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $49.06 | 3.3% | 3 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $48.25 | 3.2% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $44.62 | 3.0% | 3 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $36.87 | 2.5% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $35.10 | 2.4% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $33.93 | 2.3% | 2 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $33.57 | 2.3% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.19 | 1.2% | 1 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $16.76 | 1.1% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $16.42 | 1.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.02 | 1.1% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $15.69 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,416.69 | 81 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $69.30 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Apokyn Normalized: apokyn |
Drug | MDD US Operations, LLC | $430.61 | 26 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $154.82 | 8 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $79.25 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $67.32 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $50.92 | 2 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $48.25 | 3 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $44.62 | 3 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $36.87 | 2 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $35.13 | 1 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $35.13 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $35.10 | 2 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $34.12 | 2 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $33.93 | 2 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $33.57 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $33.18 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $33.18 | 2 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $18.19 | 1 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $17.97 | 1 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $16.76 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $16.42 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $16.02 | 1 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $14.94 | 1 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $14.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
84 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 596 | 112 |
| Donepezil Hcl | Donepezil Hcl | 590 | 135 |
| Memantine Hcl | Memantine Hcl | 565 | 128 |
| Levetiracetam | Levetiracetam | 489 | 85 |
| Primidone | Primidone | 408 | 87 |
| Topiramate | Topiramate | 372 | 77 |
| Clopidogrel | Clopidogrel Bisulfate | 312 | 84 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 292 | 65 |
| Tizanidine Hcl | Tizanidine Hcl | 292 | 52 |
| Ropinirole Hcl | Ropinirole Hcl | 245 | 52 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 213 | 25 |
| Lamotrigine | Lamotrigine | 205 | 39 |
| Zonisamide | Zonisamide | 191 | 42 |
| Alprazolam | Alprazolam | 183 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 164 | 37 |
| Divalproex Sodium | Divalproex Sodium | 162 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 148 | 30 |
| Baclofen | Baclofen | 143 | 31 |
| Tramadol Hcl | Tramadol Hcl | 143 | 24 |
| Propranolol Hcl | Propranolol Hcl | 136 | 32 |
| Carbamazepine | Carbamazepine | 135 | 26 |
| Sertraline Hcl | Sertraline Hcl | 133 | 28 |
| Clonazepam | Clonazepam | 132 | 19 |
| Galantamine Hbr | Galantamine Hbr | 131 | 26 |
| Atorvastatin Calcium | Atorvastatin Calcium | 128 | 32 |
| Pregabalin | Pregabalin | 109 | 16 |
| Oxcarbazepine | Oxcarbazepine | 104 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 102 | 21 |
| Methylphenidate Hcl | Methylphenidate Hcl | 96 | 15 |
| Meclizine Hcl | Meclizine Hcl | 95 | 26 |
| Buspirone Hcl | Buspirone Hcl | 90 | 16 |
| Celecoxib | Celecoxib | 87 | 16 |
| Carbamazepine Er | Carbamazepine | 85 | suppressed |
| Eliquis | Apixaban | 84 | 13 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 84 | 15 |
| Nortriptyline Hcl | Nortriptyline Hcl | 81 | 17 |
| Verapamil Hcl | Verapamil Hcl | 79 | 15 |
| Lorazepam | Lorazepam | 77 | 15 |
| Amantadine | Amantadine Hcl | 76 | 19 |
| Lacosamide | Lacosamide | 76 | suppressed |
| Modafinil | Modafinil | 76 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 75 | 17 |
| Trazodone Hcl | Trazodone Hcl | 75 | 17 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 71 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 70 | 18 |
| Butorphanol Tartrate | Butorphanol Tartrate | 68 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 67 | 15 |
| Cilostazol | Cilostazol | 67 | 14 |
| Memantine Hcl Er | Memantine Hcl | 65 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 65 | 12 |
| Prednisone | Prednisone | 62 | 23 |
| Promethazine Hcl | Promethazine Hcl | 62 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 62 | 15 |
| Phenobarbital | Phenobarbital | 61 | suppressed |
| Methadone Hcl | Methadone Hcl | 60 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 59 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 57 | 13 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 57 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 52 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 51 | 12 |
| Xarelto | Rivaroxaban | 51 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 48 | suppressed |
| Fentanyl | Fentanyl | 47 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 45 | suppressed |
| Simvastatin | Simvastatin | 45 | 11 |
| Neupro | Rotigotine | 43 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 42 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 40 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 39 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 38 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 38 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 35 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 35 | 11 |
| Copaxone | Glatiramer Acetate | 34 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 34 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 33 | suppressed |
| Temazepam | Temazepam | 33 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 31 | suppressed |
| Glatopa | Glatiramer Acetate | 31 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Diazepam | Diazepam | 29 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 26 | suppressed |
| Carisoprodol | Carisoprodol | 25 | suppressed |
| Epidiolex | Cannabidiol (Cbd) | 24 | suppressed |
| Lisinopril | Lisinopril | 24 | suppressed |
| Potassium Chloride | Potassium Chloride | 24 | suppressed |
| Risperidone | Risperidone | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 23 | suppressed |
| Qulipta | Atogepant | 23 | suppressed |
| Fingolimod | Fingolimod Hcl | 22 | suppressed |
| Levetiracetam Er | Levetiracetam | 22 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 22 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 20 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 20 | suppressed |
| Acetazolamide | Acetazolamide | 19 | suppressed |
| Omeprazole | Omeprazole | 19 | suppressed |
| Gilenya | Fingolimod Hcl | 18 | suppressed |
| Lamotrigine Er | Lamotrigine | 18 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Rebif | Interferon Beta-1a/Albumin | 17 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 16 | suppressed |
| Rivastigmine | Rivastigmine | 16 | suppressed |
| Keppra | Levetiracetam | 15 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 15 | suppressed |
| Phenytoin | Phenytoin | 15 | suppressed |
| Losartan Potassium | Losartan Potassium | 14 | suppressed |
| Rebif Rebidose | Interferon Beta-1a/Albumin | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Azathioprine | Azathioprine | 13 | suppressed |
| Clobazam | Clobazam | 13 | suppressed |
| Felbamate | Felbamate | 13 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 13 | suppressed |
| Meloxicam | Meloxicam | 13 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 13 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 13 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 13 | suppressed |
| Tegretol Xr | Carbamazepine | 13 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 13 | suppressed |
| Asa-Butalb-Caffeine-Codeine | Codeine/Butalbital/Asa/Caffein | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 12 | suppressed |
| Oxtellar Xr | Oxcarbazepine | 12 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 12 | suppressed |
| Savella | Milnacipran Hcl | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 11 | suppressed |
| Ubrelvy | Ubrogepant | 11 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,485.99 · 84 records | MDD US Operations, LLC | Apokyn, Briviact, HYQVIA, Hizentra, KESIMPTA, KISUNLA, Leqembi, NUPLAZID, NURTEC ODT, Nayzilam, OCTAGAM IMMUNE GLOBULIN (HUMAN), Ocrevus Zunovo, PANZYGA, PONVORY, QULIPTA, REXULTI, TYSABRI, UBRELVY, ULTOMIRIS, VUMERITY, VYALEV, VYVGART HYTRULO, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nuplazid play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error